These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Australia experiments with 'experimental use' exemption. McBratney A; Nielsen K; McMillan F Nat Biotechnol; 2004 Aug; 22(8):1023-5. PubMed ID: 15286651 [TBL] [Abstract][Full Text] [Related]
8. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry. Gillat A Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457 [No Abstract] [Full Text] [Related]
9. Protecting methods for treatment related to regenerative medicine and gene therapy in Japan. Kaneshiro K; Masuda S; Tanaka Y; Tamai K Nat Biotechnol; 2004 Mar; 22(3):343-5. PubMed ID: 14990960 [No Abstract] [Full Text] [Related]
16. Intellectual property: patents and transfer agreements preceding clinical trials and commercialization. Ross TP Retina; 2005 Dec; 25(8 Suppl):S91-S94. PubMed ID: 16374360 [No Abstract] [Full Text] [Related]
17. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
20. Excerpts from "Let's Get Back to the Competitive Market System." Originally published in November-December 1973. Grayson CJ Harv Bus Rev; 1990; 68(6):84. PubMed ID: 10107965 [No Abstract] [Full Text] [Related] [Next] [New Search]